Slide 1: Ipca Laboratories Ltd. Corporate Presentation
Ipca Laboratories Ltd. Corporate Presentation June 2026
Slide 2: About Us
About Us Incorporation Consolidated income Export to >16,000 35 9 70+ FY 2025-26 100+ Employees Manufacturing R&D years ₹9,821 Crs countries with sites labs US$1,109 Mn ~54% income share 2
Slide 3: Our Values
Our Values Adhere to Ensure safety Comply with Value Facilitate good standards comes first ethics & standards people business practices 3
Slide 4: Five Years' Highlights (Standalone)
Five Years’ Highlights Standalone 8000 ₹6,749.21 ₹6,277.75 ($797.50) 7000 ($757.82) ₹7,431.99 ₹5,925.81 ($839.23) ₹5,491.22 ($738.69) 6000 ($737.38) ₹4,301.96 5000 ₹3,940.25 ($485.82) ₹3,570.05 ($465.59) ₹3,282.39 ($430.96) 4000 ₹2,983.09 ($409.17) ($400.58) 3000 ₹3,129.43 ₹2,643.42 ₹2,707.70 ₹2,808
Slide 5: Five Years' Highlights (Consolidated)
Five Years’ Highlights Consolidated 10000 9000 ₹7,829.81 ₹9,820.78 ($945.17) ₹9,032.39 ($1,109.07) 8000 ₹6,369.94 ($1,067.28) 7000 ₹5,896.36 ($794.06) ($791.78) ₹5,255.33 6000 ₹4,894.16 ($593.49) ₹4089.87 ($578.30) 5000 ₹3,391.06 ($493.71) ₹3,077.75 ($422.72) 4000 ($413.29) ₹4,565.45 ₹4,138.23 ($515
Slide 6: Manufacturing Sites: Formulations
Manufacturing Sites Formulations
Slide 7: Manufacturing Sites: Formulations
Manufacturing Sites Formulations Indore Cluster Dewas............................. Kandla Baddi# Dehradun Pithampur...................... (ß-lactum) (2 facilities) (2 facilities) Ghaziabad# Pithampur (SEZ)............. Formulations R&D Biotech Corporate Office Overseas Mumbai Cluster Jorethang Mumba
Slide 8: Manufacturing Sites: Formulations
Manufacturing Sites Formulations Location Dosage Form Inspections / Approvals by Agencies of Athal (Dadra & Nagar Haveli) Tablets & Capsules Approved: Australia, Bahrain, Cambodia, Canada, Colombia, EU, GCC / GHC, India, Kenya, Malawi, Oman, Russia, Rwanda, Tanzania, Thailand, UAE, Uganda, Ukraine,
Slide 9: Manufacturing Sites: Active Pharmaceutical Ingredients (APIs)
Manufacturing Sites Active Pharmaceutical Ingredients (APIs)
Slide 10: Manufacturing Sites: APIs
Manufacturing Sites APIs Indore Cluster Indore............................. Dewas............................. Onyx Scientific Pithampur#..................... Chh. Sambhajinagar (Sunderland) Hingni Ratlam (2 facilities) Baroda Cluster Ranu................. Nandesari......... APIs and / or Intermedia
Slide 11: Manufacturing Sites: APIs
Manufacturing Sites APIs Location Inspections / Approvals by Agencies of Ratlam (Madhya Pradesh) Australia, Brazil, Canada, EDQM, EU, India, Japan, Korea, Mexico, Russia, Slovenia, USA, WHO Indore (Madhya Pradesh) EU, India, WHO Dewas (Madhya Pradesh) EU, India, Russia Nandesari (Gujarat) India Chh.
Slide 12: Revenue Break-up 2024-25 & 2025-26
Revenue Break-up 2024-25 & 2025-26
Slide 13: Revenue Break-up: Standalone 2025-26
Revenue Break-up Standalone 2025-26 Total Total Revenue Exports Domestic 2025-26 2025-26 2025-26 2025-26 8% 19% 42% 33% 81% 58% 67% 92% APIs Formulations Export Domestic APIs Formulations APIs Formulations Formulations APIs Domestic Exports Formulations APIs Formulations APIs 13
Slide 14: Revenue Break-up: Standalone
Revenue Break-up Standalone 2025-26 2024-25 ₹Crs Domestic Exports Total Domestic Exports Total Growth Branded Formulations 3,817.24 663.67 4,480.91 3,450.21 581.89 4,032.10 11.1% Generic / Institution / Tender Formulations - 1,418.91 1,418.91 4.89 1,336.69 1,341.58 5.8% Total Formulations 3,817.24 2
Slide 15: Financials: Standalone
Financials Standalone FY 2025-26 FY 2024-25 ₹Crs US$ Mn ₹Crs US$ Mn % Growth Total Income 7,431.39 839 6,749.21 797 10% EBIDT 1,847.36 209 1,513.33 179 22% EBIDT % 25.18% - 22.66% - - PBT # 1,562.55 176 1,281.31 151 22% PBT % 21.30% - 19.19% - - PAT # 1,132.52 128 650.76 77 74% PAT % 15.44% - 9.74%
Slide 16: Financials: Standalone Profitability
Financials Standalone Profitability FY 2025-26 FY 2024-25 24.9% 40.7% 18.9% 43.9% 26.9% 39.4% PAT PBIDT PAT PBIDT 15.44% 25.18% 9.74% 22.66% 34.4% 37.2% 33.6% PBT PBT 21.30% PBIDT PBT PAT 19.19% PBIDT PBT PAT 16
Slide 17: Financials: Standalone Business Characteristics
Financials Standalone Business Characteristics FY 2025-26 FY 2024-25 Return on Capital Employed % (PBIT / Capital Employed) 19.12% 17.24% Return on Net Worth % (PAT / Net Worth) 14.57% 13.53% Fixed Asset Turnover Ratio (Total Income / Net Fixed Assets) 2.17 2.23 Capital Employed Turnover Ratio (Tota
Slide 18: Financials: Standalone Growth
Financials Standalone Growth FY 2025-26 FY 2024-25 Net Total Income 10.1% 7.5% Domestic Sales 8.8% 12.2% Export Sales 11.4% 3.7% PBIDT 22.1% 27.2% PBT 21.9% 34.1% Net Profit 74.0% 22.7% 18
Slide 19: Financials: Standalone Q1 FY27
Financials Standalone Q1 FY27 Q1 FY26 ₹Crs US$ Mn ₹Crs US$ Mn % Growth Total Income 2,136.66 225 1,771.92 207 21% EBIDT 556.82 59 416.04 49 34% EBIDT % 26.27% - 23.82% - - PBT # 515.41 54 356.75 42 44% PBT % 24.32% - 20.42% - - PAT # 373.29 39 262.04 31 42% PAT % 17.61% - 15.00% - - # After forex ga
Slide 20: Financials: Consolidated
Financials Consolidated FY 2025-26 FY 2024-25 ₹Crs US$ Mn ₹Crs US$ Mn % Growth Total Income 9,820.78 1,109.07 9,032.39 1,067 9% EBIDT 1,998.96 226 1,693.13 200 18% EBIDT % 20.72% - 18.94% - - PBT # 1,658.95 187 1,336.19 158 24% PBT % 17.20% - 14.95% - - PAT # 1,141.12 128.87 737.68 87 55% PAT % 11.8
Slide 21: Financials: Consolidated Business Characteristics
Financials Consolidated Business Characteristics FY 2025-26 FY 2024-25 Return on Capital Employed % (PBIT / Capital Employed) 17.25% 14.98% Return on Net Worth % (PAT / Net Worth) 14.15% 10.62% Fixed Asset Turnover Ratio (Total Income / Net Fixed Assets) 1.82 1.85 Capital Employed Turnover Ratio (To
Slide 22: Financials: Consolidated Growth
Financials Consolidated Growth FY 2025-26 FY 2024-25 Net Total Income 8.7% 15.4% Domestic Sales 8.8% 12.1% Export Sales 7.4% 19.7% PBIDT 18.1% 31.4% PBT 24.2% 40.6% Net Profit 54.7% 34.8% 22
Slide 23: Financials: Consolidated Q1 FY27
Financials Consolidated Q1 FY27 Q1 FY26 ₹Crs US$ Mn ₹Crs US$ Mn % Growth Total Income 2,813.36 297 2,341.51 274 20% EBIDT 637.94 67 424.58 50 50% EBIDT % 22.88% - 18.39% - - PBT # 572.08 60 330.51 39 73% PBT % 20.52% - 14.31% - - PAT # 401.89 42 233.21 27 72% PAT % 14.41% - 10.10% - - # After forex
Slide 24: Contribution of Therapeutic Groups
Financials Standalone Contribution of Therapeutic Groups Therapeutic Segment 2025-26 Domestic 2024-25 2025-26 Export 2024-25 Non Steroidal Anti-Inflammatory Drugs (NSAID) 53% 53% Non Steroidal Anti-Inflammatory Drugs (NSAID) 31% 33% Cardiovasculars & Anti-Diabetics 17% 17% Cardiovasculars & Anti-Dia
Slide 25: Branded Formulations: Domestic
Branded Formulations Domestic
Slide 26: Branded Formulations: Domestic
Branded Formulations Domestic All India Rank IQVIA 24 Market leaders in Therapy Focused Over 4,000 Rheumatoid Arthritis 16th (MAT Jun’26) Marketing Divisions Wholesalers & Anti-malarials 24 Depots & Field Strength 6 brands among 1 C&F agent (PSR / BA)-7187 top 300 brands (Zerodol-SP, Zerodol-P, HCQS
Slide 27: Branded Formulations: Domestic Sales
Branded Formulations Domestic ₹3,817.24 4000 ($431 Mn) ₹3,455.10 3500 ₹3,097.16 ($408 Mn) ₹2,760.71 ($374 Mn) 3000 ($344 Mn) 2500 2000 1500 1000 500 2025-26 0 2022-23 2023-24 2022-23 2023-24 2024-25 2025-26 2024-25 Figures in Crores. Sales 27
Slide 28: Domestic Future Growth Drivers
Branded Formulations Domestic Future Growth Clinical research as a tool to launch innovative combination Drivers formulations / NDDS Strong brand building with focused promotion In-licensing / out-licensing to build business in the promoted therapy Portfolio optimisation, strategies to identify need
Slide 29: International Business
International Business
Slide 30: International Business
International Business Recognised Field-force to promote brands Five Star Export in more than Registrations in House 30 countries 61 countries Products of the company 42% sales Marketing offices in are now exported to over From exports 12 countries 100 countries across the globe 30
Slide 31: International Business Sales
International Business 3500 ₹3,129.43 ($353 Mn) ₹2,707.70 ₹2,808.96 3000 ₹2,643.42 ($327 Mn) ($332 Mn) ($330 Mn) 2500 2000 1500 1000 500 2025-26 0 2022-23 2023-24 2022-23 2023-24 2024-25 2025-26 2024-25 Figures in Crores. Sales 31
Slide 32: Continent-wise Exports 2025-26
International Business Continent-wise Exports 2025-26 (₹Crs) Continent Formulations APIs Total % Contribution Europe 522.75 361.84 884.59 28% Africa 538.56 55.92 594.48 19% Americas 344.03 321.30 665.33 21% Asia 134.66 263.51 398.17 13% CIS 228.21 40.97 269.18 9% Australasia 314.37 3.31 317.68 10% T
Slide 33: International Formulations
International Formulations
Slide 34: International Formulations Sales
International Formulations ₹2,082.58 2200 ₹1,918.58 ($235 Mn) 2000 ₹1,775.32 ($227 Mn) ₹1,639.19 ($214 Mn) 1800 ($204 Mn) 1600 1400 1200 1000 800 600 400 200 2025-26 0 2022-23 2023-24 2022-23 2023-24 2024-25 2025-26 2024-25 Figures in Crores. Sales 34
Slide 35: International Branded Formulations
International Branded Formulations
Slide 36: International Branded Formulations Sales
International Branded Formulations ₹663.67 690 ($75 Mn) 660 630 ₹581.89 600 ($69 Mn) 570 ₹526.70 540 ₹504.79 ($64 Mn) 510 ($63 Mn) 480 450 420 390 360 2025-26 330 2022-23 2023-24 2022-23 2023-24 2024-25 2025-26 2024-25 Figures in Crores. Sales 36
Slide 37: International Branded Formulations Growth Drivers
International Branded Formulations Future Growth Thrust on brand building in Pain, CVS, CNS, Anti-infective Drivers and Anti-malarial segments Geographical expansion in covered countries through additional field force Expansion in business lines - Institutions and Distributors Introduction of new pr
Slide 38: International Generics / Institution / Tender
International Generics / Institution / Tender
Slide 39: International Generics / Institution / Tender
International Generics / Institution / Tender Products Products Under 1600 ₹1,418.91 Country Registered Registration ₹1,336.69 ($160Mn) 1400 ₹1,248.62 ($158 Mn) United Kingdom ($151 Mn) 64 43 ₹1,134.40 / Europe 1200 ($141 Mn) Australia / 76 6 1000 New Zealand 800 South Africa 53 10 600 United States
Slide 40: International Generics Future Growth Drivers
International Generics Future Growth Drivers Dossiers developed by company approved in UK are being taken for registration in other EU countries Formulations registered to be backed by own API Sale of generic dossiers with or without supply agreements Contract manufacturing arrangements Future Growt
Slide 41: International Active Pharmaceutical Ingredients (APIs)
International Active Pharmaceutical Ingredients (APIs)
Slide 42: International APIs Sales
International APIs 1200 ₹1,046.85 ₹1,004.23 ($118 Mn) ($125 Mn) ₹932.38 1000 ($113 Mn) ₹890.38 ($105 Mn) 800 600 400 200 2025-26 0 2022-23 2023-24 2022-23 2023-24 2024-25 2025-26 2024-25 Figures in Crores. Sales 42
Slide 43: APIs - Drug Master Files
International APIs - Drug Master Files API-DMFs Filed as on Jun’26 (Based on DMFs Sr. No.) API DMF Canada- Japan- Sr. No. Sr. No. Name of the API US-FDA HPFB WHO PMDA Australia EQDM 1 1 Alendronate Sodium - - - 2 2 Allopurinol - - CEP 3 Amlodipine Besylate - - - - - 3 4 Amlodipine Besylate (AK4 Proc
Slide 44: APIs - Drug Master Files
International APIs - Drug Master Files API-DMFs Filed as on Jun’26 (Based on DMFs Sr. No.) API DMF Canada- Japan- Sr. No. Sr. No. Name of the API US-FDA HPFB WHO PMDA Australia EQDM 11 12 Benzarone - - - - - 12 13 Benzbromarone - - - - - 13 14 Bisoprolol Fumarate - - - 14 15 Bupropion Hydrochloride
Slide 45: APIs - Drug Master Files
International APIs - Drug Master Files API-DMFs Filed as on Jun’26 (Based on DMFs Sr. No.) API DMF Canada- Japan- Sr. No. Sr. No. Name of the API US-FDA HPFB WHO PMDA Australia EQDM 20 23 Citalopram HBR - - - - - 21 24 Dihydroartemesinin - - - - - - 22 25 Donepezil Hydrochloride Monohydrate - - - -
Slide 46: APIs - Drug Master Files
International APIs - Drug Master Files API-DMFs Filed as on Jun’26 (Based on DMFs Sr. No.) API DMF Canada- Japan- Sr. No. Sr. No. Name of the API US-FDA HPFB WHO PMDA Australia EQDM 29 34 Frusemide - - - - CEP 30 35 Fluoxetine HCl - - - - 31 36 Felodipine - - - - - 32 37 Glimepiride - - - 38 Hydroch
Slide 47: APIs - Drug Master Files
International APIs - Drug Master Files API-DMFs Filed as on Jun’26 (Based on DMFs Sr. No.) API DMF Canada- Japan- Sr. No. Sr. No. Name of the API US-FDA HPFB WHO PMDA Australia EQDM 38 45 Lamotrigine - - - - - 46 Losartan Potassium (LB4 Process) - - - - - 39 47 Losartan Potassium (LB7 Process) - - -
Slide 48: APIs - Drug Master Files
International APIs - Drug Master Files API-DMFs Filed as on Jun’26 (Based on DMFs Sr. No.) API DMF Canada- Japan- Sr. No. Sr. No. Name of the API US-FDA HPFB WHO PMDA Australia EQDM 56 Metoclopramide HCl - - - - CEP 47 57 Metoclopramide HCl (M Process) - - - - 48 58 Metoprolol Succinate - - - CEP 59
Slide 49: APIs - Drug Master Files
International APIs - Drug Master Files API-DMFs Filed as on Jun’26 (Based on DMFs Sr. No.) API DMF Canada- Japan- Sr. No. Sr. No. Name of the API US-FDA HPFB WHO PMDA Australia EQDM 56 67 Piperaquine Phosphate - - - - - - 57 68 Primaquine Phosphate - - - - - - 58 69 Proguanil Hydrochloride - - - - -
Slide 50: APIs - Drug Master Files
International APIs - Drug Master Files API-DMFs Filed as on Jun’26 (Based on DMFs Sr. No.) API DMF Canada- Japan- Sr. No. Sr. No. Name of the API US-FDA HPFB WHO PMDA Australia EQDM 78 Telmisartan - - - - - 66 79 Telmisartan (WT6 Process) - - - - - 80 Telmisartan (WT3A Process) - - - - - - 67 81 Tor
Slide 51: International APIs Future Growth Drivers
International APIs Consolidate API business of Sartans across the globe Future Growth Drivers Long term strategic tie-ups with major South American / European formulators Leverage the customer base of more than 1000 customers spread across 90 countries is well laid down platform to introduce new pip
Slide 52: Research & Development: APIs & Formulations
Research & Development APIs & Formulations
Slide 53: R&D Spending
Research & Development APIs & Formulations Year ₹Crs % to Sales 260 ₹239.81 4.50% 3.29% 2021-22 141.46 2.63% 230 ₹207.08 4.00% 3.12% 210 3.50% 2022-23 156.49 2.71% ₹146.46 ₹156.49 ₹161.50 3.00% 180 2.71% 2.64% 2023-24 161.50 2.64% 2.63% 150 2.50% 2024-25 207.08 3.12% 120 2.00% 90 1.50% 2025-26 239.8
Slide 54: Research & Development: APIs & Formulations
Research & Development APIs & Formulations Current scientist manpower of 650+ Research focus on developing APIs with non-infringing process and development of finished dosage forms Development of NDDS for domestic and international market 287 patent applications filed Biotech / fermentation research
Slide 55: Overview of Advanced Biotech Lab
Overview of Advanced Biotech Lab Biosimilar R&D and Bio-manufacturing Established “state-of-the-art” R&D in 2015 for Mammalian based mAbs Capable of in-house development from “Clone to Commercialisation” Single-use CGMP Bio-manufacturing Facility (DS+DP+QC) with 500 and 2000L capacity for clinical a
Slide 56: Strong Biosimilar Pipelines
Strong Biosimilar Pipelines Molecules: Anti-cancer , Anti-inflammatory and Ophthalmic mAbs Stage of Development 10 Monoclonal antibodies (mAbs) and Molecules Development Pre-clinical Clinical Trials MAA / Launch One Non-mAb Biosimilar at various stages UK / CA / IN / EU of the development / USA
Slide 57: Thank You
Thank You No part of this corporate presentation may be re-produced, quoted or circulated without prior approval of Ipca Laboratories Limited. This presentation may include forward looking statements based on our current business expectations. Our actual results may differ from what is projected in